After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more_老虎社区_美港股上老虎

After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more

StreetInsider2021-10-19

After-Hours Stock Movers: Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

255

W00dy
·2021-10-19
Like pls, thanks
回复
1
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
SanWangtikup
·2021-10-19
Like pls
回复
1
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
LennartM
·2021-10-19
like please
回复
2
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
- Blackbunny:
  done
  2021-10-19
  回复
  举报
Chris68
·2021-10-19
Good to know
回复
3
举报
收起
- Chris68:
  Yup
  2021-10-19
  回复
  举报
Bentofighter
·2021-10-19
Pls like
回复
2
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
Cindyoxy
·2021-10-19
Like pls
回复
3
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
- Bentofighter:
  Ok
  2021-10-19
  回复
  举报
- LennartM:
  done
  2021-10-19
  回复
  举报
SamYYL
·2021-10-19
Like
回复
7
举报
收起
- DMC8:
  Ok
  2021-10-19
  回复
  举报
- PSYCHO82:
  Ok
  2021-10-19
  回复
  举报
- 滚股怪:
  Ok
  2021-10-19
  回复
  举报
小虎一飞冲天
·2021-10-19
Like pls. Thanks.
回复
5
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
skylander
·2021-10-19
Like pls
回复
6
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
saral
·2021-10-19
Like pls thks.
回复
4
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-23
  回复
  举报
Al3x
·2021-10-19
Like
回复
5
举报
收起
- saral:
  Ok
  2021-10-19
  回复
  举报
happymoney
·2021-10-19
Shocking
回复
4
举报
收起
- happymoney:
  Attack
  2021-10-19
  回复
  举报
41a25b3d
·2021-10-19
.
回复
5
举报
Desmond669
·2021-10-19
Yes
回复
5
举报
收起
- JackTL:
  gogo
  2021-10-19
  回复
  举报
- 41a25b3d:
  .
  2021-10-19
  回复
  举报
- 小虎一飞冲天:
  👍🏼
  2021-10-19
  回复
  举报
JCai
·2021-10-19
K
回复
2
举报
收起
- JCai:
  mm
  2021-10-19
  回复
  举报
- Desmond669:
  Ok
  2021-10-19
  回复
  举报
Dreamchaser9
·2021-10-19
Ok
回复
2
举报
收起
- WR_C:
  [Strong]
  2021-10-19
  回复
  举报
ToTheM00N
·2021-10-19
Like
回复
5
举报
收起
- Dreamchaser9:
  Done
  2021-10-19
  回复
  举报
Newbie_21
·2021-10-19
Ok
回复
4
举报
收起
- ToTheM00N:
  Ok
  2021-10-19
  回复
  举报
- 滚股怪:
  Oookk
  2021-10-19
  回复
  举报
Goodmeng
·2021-10-19
Great
回复
3
举报
Unknown934
·2021-10-19
Yes
回复
5
举报
收起
- Unknown934:
  Comment
  2021-10-19
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2176774120?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-19 07:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2176774120","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ETTX","symbol_name":"Entasis Therapeutics Holdings Inc.","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","article_id":"2176774120","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","pubTimestamp":1634599410,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","EVER":"Everquote Inc.","TASK":"TaskUs Inc."},"translate_title":"下班后股票搬运工：Entasis疗法、皮肤疗法、TaskUs等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRMA":0.9,"ETTX":0.9,"EVER":0.9,"STLD":0.9,"TASK":0.9},"content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":859026057,"gmtCreate":1634641801928,"gmtModify":1634641802495,"author":{"id":"4089162592476240","authorId":"4089162592476240","name":"W00dy","avatar":"https://static.tigerbbs.com/e321bf45dd05336a6b9f1c27eb0ecde8","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like pls, thanks","listText":"Like pls, thanks","text":"Like pls, thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859026057","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294365,"gmtCreate":1634947223999,"gmtModify":1634947224031,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":859026057,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":859034194,"gmtCreate":1634636780745,"gmtModify":1634636948850,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859034194","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294369,"gmtCreate":1634947232278,"gmtModify":1634947232317,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":859034194,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850404496,"gmtCreate":1634613429819,"gmtModify":1634613430763,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"like please","listText":"like please","text":"like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/850404496","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294371,"gmtCreate":1634947239536,"gmtModify":1634947239578,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850404496,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6249428,"gmtCreate":1634615051166,"gmtModify":1634631651885,"authorId":3582075354763697,"author":{"id":3582075354763697,"authorId":3582075354763697,"name":"Blackbunny","avatar":"https://static.tigerbbs.com/7c19a775624a3a537472a142b0aaf453","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850404496,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":850401221,"gmtCreate":1634612875138,"gmtModify":1634612877550,"author":{"id":"3575974639321365","authorId":"3575974639321365","name":"Chris68","avatar":"https://static.tigerbbs.com/1ae39a12c3ba237f3b001689ec9a549b","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Good to know&nbsp;","listText":"Good to know&nbsp;","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850401221","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6249127,"gmtCreate":1634612881977,"gmtModify":1634631672501,"authorId":3575974639321365,"author":{"id":3575974639321365,"authorId":3575974639321365,"name":"Chris68","avatar":"https://static.tigerbbs.com/1ae39a12c3ba237f3b001689ec9a549b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850401221,"type":1,"supId":0,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"}],"langContent":"CN"},{"id":850577656,"gmtCreate":1634612424203,"gmtModify":1634612424597,"author":{"id":"3583478720415511","authorId":"3583478720415511","name":"Bentofighter","avatar":"https://static.tigerbbs.com/3d3b444e1397cd8d1ec1b18c5c8c5db5","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850577656","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294375,"gmtCreate":1634947247085,"gmtModify":1634947247195,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850577656,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850549704,"gmtCreate":1634610961478,"gmtModify":1634610961603,"author":{"id":"3582080374471215","authorId":"3582080374471215","name":"Cindyoxy","avatar":"https://static.tigerbbs.com/6ce8843c8a2fd64a899130762430331d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/850549704","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294380,"gmtCreate":1634947255303,"gmtModify":1634947255332,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850549704,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6249027,"gmtCreate":1634612429882,"gmtModify":1634631680265,"authorId":3583478720415511,"author":{"id":3583478720415511,"authorId":3583478720415511,"name":"Bentofighter","avatar":"https://static.tigerbbs.com/3d3b444e1397cd8d1ec1b18c5c8c5db5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850549704,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6249210,"gmtCreate":1634613444936,"gmtModify":1634631668039,"authorId":3576017931077934,"author":{"id":3576017931077934,"authorId":3576017931077934,"name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850549704,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"CN"},{"id":850564549,"gmtCreate":1634609234496,"gmtModify":1634609855824,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/850564549","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6248375,"gmtCreate":1634609376972,"gmtModify":1634631729742,"authorId":3579992296424941,"author":{"id":3579992296424941,"authorId":3579992296424941,"name":"DMC8","avatar":"https://static.tigerbbs.com/65aa8f5f6299558ce2ab36482793f750","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850564549,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6248588,"gmtCreate":1634610335696,"gmtModify":1634631715069,"authorId":3584840087767846,"author":{"id":3584840087767846,"authorId":3584840087767846,"name":"PSYCHO82","avatar":"https://static.tigerbbs.com/c7ab6b697c630c3b99e18227fdd119f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850564549,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6249734,"gmtCreate":1634616595577,"gmtModify":1634631625499,"authorId":4091089381144950,"author":{"id":4091089381144950,"authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850564549,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":850564659,"gmtCreate":1634609205010,"gmtModify":1634609855017,"author":{"id":"3582098623642517","authorId":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like pls. Thanks.","listText":"Like pls. Thanks.","text":"Like pls. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850564659","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294390,"gmtCreate":1634947266218,"gmtModify":1634947266264,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850564659,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850580494,"gmtCreate":1634608097466,"gmtModify":1634608239852,"author":{"id":"4087989241523320","authorId":"4087989241523320","name":"skylander","avatar":"https://static.tigerbbs.com/1c70a5b34449eb6137e74ae1fefb2ea0","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850580494","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294395,"gmtCreate":1634947274243,"gmtModify":1634947274285,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850580494,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850519801,"gmtCreate":1634607544194,"gmtModify":1634607604373,"author":{"id":"3568944508199908","authorId":"3568944508199908","name":"saral","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Like pls thks.","listText":"Like pls thks.","text":"Like pls thks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850519801","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294399,"gmtCreate":1634947281280,"gmtModify":1634947281381,"authorId":3567307840510045,"author":{"id":3567307840510045,"authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850519801,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850592648,"gmtCreate":1634606695024,"gmtModify":1634606695403,"author":{"id":"4088815138354210","authorId":"4088815138354210","name":"Al3x","avatar":"https://static.tigerbbs.com/76537eea7f5e56814a3866c383a688d2","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850592648","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6247958,"gmtCreate":1634607561285,"gmtModify":1634631764195,"authorId":3568944508199908,"author":{"id":3568944508199908,"authorId":3568944508199908,"name":"saral","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850592648,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":850505999,"gmtCreate":1634606110551,"gmtModify":1634606111059,"author":{"id":"3569807126010989","authorId":"3569807126010989","name":"happymoney","avatar":"https://static.tigerbbs.com/c7b835f693b89bd9b980cc013a40c669","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Shocking&nbsp;","listText":"Shocking&nbsp;","text":"Shocking","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850505999","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6247585,"gmtCreate":1634606124305,"gmtModify":1634631793922,"authorId":3569807126010989,"author":{"id":3569807126010989,"authorId":3569807126010989,"name":"happymoney","avatar":"https://static.tigerbbs.com/c7b835f693b89bd9b980cc013a40c669","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850505999,"type":1,"supId":0,"prevId":0,"content":"<u>Attack</u>","text":"<u>Attack</u>","html":"<u>Attack</u>"}],"langContent":"CN"},{"id":850272443,"gmtCreate":1634605550915,"gmtModify":1634605551274,"author":{"id":"3582279484837092","authorId":"3582279484837092","name":"41a25b3d","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850272443","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":850248065,"gmtCreate":1634604768860,"gmtModify":1634604769434,"author":{"id":"3562118563279867","authorId":"3562118563279867","name":"Desmond669","avatar":"https://static.tigerbbs.com/e2484115c94d3471cb46f20ea7598b4a","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/850248065","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6247427,"gmtCreate":1634605448431,"gmtModify":1634631807258,"authorId":3581557493426416,"author":{"id":3581557493426416,"authorId":3581557493426416,"name":"JackTL","avatar":"https://static.tigerbbs.com/851801800e7dc3457e5e60048a987880","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850248065,"type":1,"supId":0,"prevId":0,"content":"gogo","text":"gogo","html":"gogo"},{"id":6247455,"gmtCreate":1634605557461,"gmtModify":1634631804744,"authorId":3582279484837092,"author":{"id":3582279484837092,"authorId":3582279484837092,"name":"41a25b3d","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850248065,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":6248341,"gmtCreate":1634609231637,"gmtModify":1634631732361,"authorId":3582098623642517,"author":{"id":3582098623642517,"authorId":3582098623642517,"name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850248065,"type":1,"supId":0,"prevId":0,"content":"👍🏼","text":"👍🏼","html":"👍🏼"}],"langContent":"CN"},{"id":850255343,"gmtCreate":1634604322899,"gmtModify":1634604324538,"author":{"id":"3574897713454581","authorId":"3574897713454581","name":"JCai","avatar":"https://static.tigerbbs.com/a4408059854d4abfa5d3e8513d447a16","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/850255343","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6247164,"gmtCreate":1634604328964,"gmtModify":1634631828745,"authorId":3574897713454581,"author":{"id":3574897713454581,"authorId":3574897713454581,"name":"JCai","avatar":"https://static.tigerbbs.com/a4408059854d4abfa5d3e8513d447a16","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850255343,"type":1,"supId":0,"prevId":0,"content":"<u>mm</u>","text":"<u>mm</u>","html":"<u>mm</u>"},{"id":6247260,"gmtCreate":1634604765005,"gmtModify":1634631820674,"authorId":3562118563279867,"author":{"id":3562118563279867,"authorId":3562118563279867,"name":"Desmond669","avatar":"https://static.tigerbbs.com/e2484115c94d3471cb46f20ea7598b4a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850255343,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":850253380,"gmtCreate":1634604028539,"gmtModify":1634604029836,"author":{"id":"3581782846197879","authorId":"3581782846197879","name":"Dreamchaser9","avatar":"https://static.tigerbbs.com/f4f8f000953179179078bdd5e6f748b6","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850253380","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6247414,"gmtCreate":1634605391883,"gmtModify":1634631808347,"authorId":3575335798971548,"author":{"id":3575335798971548,"authorId":3575335798971548,"name":"WR_C","avatar":"https://static.tigerbbs.com/637290a50ca781cef43611a2b68b9b54","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850253380,"type":1,"supId":0,"prevId":0,"content":"[Strong]","text":"[Strong]","html":"[Strong]"}],"langContent":"CN"},{"id":850229478,"gmtCreate":1634603340560,"gmtModify":1634603341144,"author":{"id":"3581730511233431","authorId":"3581730511233431","name":"ToTheM00N","avatar":"https://static.tigerbbs.com/7b77b689650adddd8a8560dc89fcb930","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850229478","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6247087,"gmtCreate":1634604042219,"gmtModify":1634631835387,"authorId":3581782846197879,"author":{"id":3581782846197879,"authorId":3581782846197879,"name":"Dreamchaser9","avatar":"https://static.tigerbbs.com/f4f8f000953179179078bdd5e6f748b6","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850229478,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":850267430,"gmtCreate":1634603243294,"gmtModify":1634603245097,"author":{"id":"3581562486795328","authorId":"3581562486795328","name":"Newbie_21","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/850267430","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6246846,"gmtCreate":1634603345503,"gmtModify":1634631852658,"authorId":3581730511233431,"author":{"id":3581730511233431,"authorId":3581730511233431,"name":"ToTheM00N","avatar":"https://static.tigerbbs.com/7b77b689650adddd8a8560dc89fcb930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850267430,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6249595,"gmtCreate":1634615867977,"gmtModify":1634631637176,"authorId":4091089381144950,"author":{"id":4091089381144950,"authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850267430,"type":1,"supId":0,"prevId":0,"content":"Oookk","text":"Oookk","html":"Oookk"}],"langContent":"CN"},{"id":850266855,"gmtCreate":1634602942120,"gmtModify":1634602943378,"author":{"id":"3575588910593021","authorId":"3575588910593021","name":"Goodmeng","avatar":"https://static.tigerbbs.com/96dc060537e6112d51026eaa7dd4db92","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850266855","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":850282518,"gmtCreate":1634602418320,"gmtModify":1634602424909,"author":{"id":"3568773327054096","authorId":"3568773327054096","name":"Unknown934","avatar":"https://static.tigerbbs.com/8b3574572ddefc308a01b8cc301667c4","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850282518","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc","STLD":"Steel Dynamics","ETTX":"Entasis Therapeutics Holdings Inc.","TASK":"TaskUs Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6246586,"gmtCreate":1634602426640,"gmtModify":1634631876301,"authorId":3568773327054096,"author":{"id":3568773327054096,"authorId":3568773327054096,"name":"Unknown934","avatar":"https://static.tigerbbs.com/8b3574572ddefc308a01b8cc301667c4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850282518,"type":1,"supId":0,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":255,"commentSize":30,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}